Case report: CD38-directed CAR-T cell therapy: A novel immunotherapy targeting CD38- positive blasts overcomes TKI and chemotherapy resistance of myeloid chronic myeloid leukemia in blastic phase. Here, CD38 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.